Funding is requested for an ImageStreamX-markII (ISX-MKII) imaging flow cytometer to replace a first generation ImageStream-100 cytometer. At the time of its commercial introduction in 2006, the IS-100 uniquely combined flow cytometry with quantitative image analysis. In anticipation of the applicability of this then novel platform or many of our NIH-funded users, the IS100 was acquired. The introduction of the ImageStream technology to our user group has been very successful leading to the award of 3 additional NIH-funded grants that rely heavily on this technology. Based on the success of implementing the IS100 at RPCI, the clear benefit of the technology to our research base and its high usage, an additional ImageStream, the ImageStreamX (ISX) was purchased as a second ImageStream platform with Institute support in 2009 and upgraded to the third generation ISX-MK-II in 2012. In addition, RPCI also invested in the expanded computational and data storage infrastructure and personnel needed in support of the increasing demand for this technology by the RPCI research base. The advanced ImageStream application demands of our user base enabled by the technological advancements implemented in the 3rd generation ISX-MKII have rendered the IS100 obsolete. Thus, the ISX-MK-II currently carries 100% of the work load and is operating at >80% capacity without a functional back up. The purchase of an additional ISX-MKII to replace the now obsolete IS100 will allow our facility to meet the increasing demand for advanced ImageStream applications and provide backup capability when the current machine is out-of-service due to maintenance or repair needs.

Agency
National Institute of Health (NIH)
Institute
Office of The Director, National Institutes of Health (OD)
Type
Biomedical Research Support Shared Instrumentation Grants (S10)
Project #
1S10OD018048-01
Application #
8639824
Study Section
Special Emphasis Panel (ZRG1-CB-D (31))
Program Officer
Levy, Abraham
Project Start
2014-06-01
Project End
2015-05-31
Budget Start
2014-06-01
Budget End
2015-05-31
Support Year
1
Fiscal Year
2014
Total Cost
$399,500
Indirect Cost
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Shenoy, Gautam N; Loyall, Jenni; Maguire, Orla et al. (2018) Exosomes Associated with Human Ovarian Tumors Harbor a Reversible Checkpoint of T-cell Responses. Cancer Immunol Res 6:236-247
La Shu, Shin; Yang, Yunchen; Allen, Cheryl L et al. (2018) Metabolic reprogramming of stromal fibroblasts by melanoma exosome microRNA favours a pre-metastatic microenvironment. Sci Rep 8:12905
Minderman, Hans; Maguire, Orla; O'Loughlin, Kieran L et al. (2017) Total cellular protein presence of the transcription factor IRF8 does not necessarily correlate with its nuclear presence. Methods 112:84-90
Greene, Christopher J; Attwood, Kristopher; Sharma, Nitika J et al. (2017) Transferrin receptor 1 upregulation in primary tumor and downregulation in benign kidney is associated with progression and mortality in renal cell carcinoma patients. Oncotarget 8:107052-107075
Maguire, Orla; Chen, George L; Hahn, Theresa E et al. (2017) Quantifying MHC dextramer-induced NFAT activation in antigen-specific T cells as a functional response parameter. Methods 112:75-83
Maguire, Orla; Wallace, Paul K; Minderman, Hans (2016) Fluorescent In Situ Hybridization in Suspension by Imaging Flow Cytometry. Methods Mol Biol 1389:111-26